| 1156 Anti-inflammatory Action of Stannous Fluoride | ||
|
L.A. GILDEA, L.T. LAUGHLIN, B.Y. HO, R.A. GRAYLING, H.E. MATHENY, D.S. BUSHNELL, and J.L. WINSTON, Procter & Gamble Company, Mason, OH, USA Stannous Fluoride (SnF2) is a broad spectrum anti-bacterial agent which has been clinically proven in dentifrice to help control supragingival plaque and gingivitis. Objective: The purpose of this study was to evaluate the potential anti-inflammatory action of SnF2, independent of the anti-bacterial action. Methods: The inhibition of several host and bacterial pro-inflammatory enzymes by SnF2 was tested in vitro. The inhibition of purified human mammalian matrix metalloproteinases (MMPs) and IL-1 beta converting enzyme (ICE) were measured by the cleavage of the fluorogenic substrates Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 and N-acetyl-Trp-Glu-His-Asp-AMC, respectively. The activity of Porphyromonas gingivalis R-gingipain was tested on the fluorogenic substrate Z-Phe-Arg-AMC•HCl. Results: SnF2 demonstrated inhibition of several mammalian matrix metalloproteinase subtypes and other pro-inflammatory enzymes, with a rank order of potency of gingipain > MMP13 > MMP3 > MMP2 > ICE > MMP9 > MMP1. Conclusions: These findings indicate that SnF2 demonstrates direct anti-inflammatory activity and prevention of tissue destruction in addition to its well established anti-bacterial activity against gingivitis. | ||
| Seq #126 - Microbes and Oral Infections 3:30 PM-4:45 PM, Thursday, March 22, 2007 Ernest N. Morial Convention Center Exhibit Hall I2-J | ||
|
Back to the Microbiology / Immunology and Infection Control Program
| ||